Treatment with all-trans retinoic acid (ATRA) was used in vitro on induced pluripotent stem cell-derived cardiomyocytes derived from a patient with DCM and a known RBM20 mutation and managed, in this setting, to improve the splicing defects and the impaired contractility. Here, RBM20 is linked to familial dilated cardiomyopathy.